Beta Bionics CCO sells 775 shares at $15.52

Beta Bionics’ Chief Commercial Officer executed a small 10b5-1 planned share sale, retaining over eighty-six thousand shares.

Available on EDGAR 09/15/2026 - 04:15 PM EDT Accepted by SEC EDGAR 09/15/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) reported that Chief Commercial Officer Mark Hopman sold 775 shares of common stock on September 14, 2026 at a price of $15.52 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 10, 2026, and Hopman now holds 86,382 shares directly.

Insider Trade Summary 10b5-1

Net Seller: 775 shares

Net Sell 1 txn

Insider Hopman Mark

Role Chief Commercial Officer

Sold 775 shs ($12K)

Share of Position Sold 0.89%

Type	Security	Shares	Price	Value
Sale	Common Stock F1	775	$15.52	$12K

Holdings After Transaction: Common Stock — 86,382 shares (Direct)

Holdings Before and After: Common Stock, 87,157 to 86,382 shares (Direct)

Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.

Key Figures

Shares sold: 775 shares Sale price per share: $15.52 per share Shares owned after transaction: 86,382 shares +2 more

5 metrics

Shares sold 775 shares Common stock sale by Chief Commercial Officer on September 14, 2026

Sale price per share $15.52 per share Price for the 775 shares of common stock sold on September 14, 2026

Shares owned after transaction 86,382 shares Direct holdings of Mark Hopman after the September 14, 2026 sale

Net insider share change 775 shares sold Net effect of reported insider activity in this Form 4

Rule 10b5-1 plan adoption date June 10, 2026 Date the trading plan governing the reported sale was adopted

Key Terms

Rule 10b5-1 Plan, pre-arranged trading plan, common stock

3 terms

Rule 10b5-1 Plan regulatory

"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

pre-arranged trading plan regulatory

"The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 10, 2026."

A pre-arranged trading plan is a set of instructions created in advance that specifies how and when an investor will buy or sell securities. It helps ensure that trades are made in a planned, transparent way, reducing the risk of making impulsive decisions or trading based on inside information. This plan provides a clear structure, giving investors confidence that their trades follow their original intentions, even if market conditions change.

common stock financial

"sold 775 shares of common stock on September 14, 2026 at a price of $15.52 per share"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BBNX disclose for Mark Hopman?

Beta Bionics disclosed that Chief Commercial Officer Mark Hopman sold 775 shares of common stock on September 14, 2026 at $15.52 per share, in a transaction made under a pre-arranged Rule 10b5-1 trading plan.

How many Beta Bionics (BBNX) shares did Mark Hopman sell and at what price?

Mark Hopman sold 775 shares of Beta Bionics common stock at a price of $15.52 per share on September 14, 2026, as reported in the insider filing.

How many BBNX shares does Mark Hopman own after the reported sale?

After the reported sale, Mark Hopman directly owns 86,382 shares of Beta Bionics common stock, according to the ownership figure stated following the transaction.

Was the BBNX insider sale by Mark Hopman under a Rule 10b5-1 plan?

Yes. The filing states that the 775 shares were sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026, indicating the trade was made under a pre-arranged trading plan.

What is the total size of the net insider activity reported for BBNX?

The insider activity consists of a net sale of 775 shares of Beta Bionics common stock, with no reported purchases, option exercises, gifts, or derivative transactions in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		S(1)		775	D	$15.52	86,382	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.

	/s/ Stephen Feider, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)